Identifying genetic markers to improve treatment for pediatric osteosarcoma
Molecular Signatures of Biologic Behavior in Pediatric Osteosarcoma
This study is looking to create a blood test for kids and young adults with osteosarcoma that can help doctors understand how serious the cancer is and how well different treatments might work for each patient, so they can tailor the treatment to be just right for them.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10983313 on NIH RePORTER |
What this research studies
This research focuses on pediatric osteosarcoma, a common bone cancer in children and young adults, aiming to develop a blood test that can predict patient outcomes. By analyzing exosomes, which are tiny particles released by cells, the study seeks to identify genetic signatures that indicate how aggressive the cancer is and how well patients might respond to treatment. This could allow for more personalized treatment plans, where some patients receive less aggressive therapy while others may be directed towards more intensive treatments or clinical trials. The goal is to reduce the side effects of treatment and improve long-term survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with osteosarcoma.
Not a fit: Patients with osteosarcoma who are older than 25 years or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more tailored treatments for pediatric osteosarcoma, minimizing unnecessary aggressive therapies and their associated long-term health risks.
How similar studies have performed: Previous research has shown promise in using genetic markers for prognosis in various cancers, suggesting that this approach could be effective for osteosarcoma as well.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Makielski, Kelly M — University of Minnesota
- Study coordinator: Makielski, Kelly M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.